NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 34 min ago

Notice of ECHO's Withdrawal from Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research (NOT-OD-24-096)

Wed, 2024-07-31 12:39
Notice NOT-OD-24-162 from the NIH Guide for Grants and Contracts

Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)

Wed, 2024-07-31 12:38
Funding Opportunity RFA-AG-25-023 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias.This NOFO supports exploratory and developmental grant (R21) applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified RNA modifications.

Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) (U01 Clinical Trial Optional)

Wed, 2024-07-31 12:38
Funding Opportunity RFA-DK-25-020 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) is a single source application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-25-019 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).

The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)

Wed, 2024-07-31 12:38
Funding Opportunity RFA-DK-25-019 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC). The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-25-018 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.

Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)

Wed, 2024-07-31 12:37
Funding Opportunity RFA-AG-25-022 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to catalyze innovative research to elucidate the molecular landscape and functional implications of RNA modifications in brain aging and Alzheimer's disease (AD) and AD-related dementias (ADRD). AD-related dementias include Lewy body dementia (LBD), frontotemporal dementia (FTD), vascular cognitive impairment/dementia (VCI/D), and mixed dementias. This NOFO supports applications focused on uncovering novel mechanisms underlying RNA modification-mediated processes and their impact on brain aging and the pathogenesis and progression of AD/ADRD. The ultimate goal is to identify targets for biomarker discovery and drug development for AD/ADRD.

Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)

Wed, 2024-07-31 12:36
Funding Opportunity RFA-AG-25-021 from the NIH Guide for Grants and Contracts. The goal of the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program is to provide support for early-career physician-scientists trained in medical or surgical specialties and early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. In support of the program's goal, this GEMSSTAR NOFO provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.

NIHs Adoption of Common Forms for Biographical Sketch and Current and Pending (Other) Support by May 25, 2025

Wed, 2024-07-31 04:27
Notice NOT-OD-24-163 from the NIH Guide for Grants and Contracts

Revisions to the Fellowship Application and Review Process Webinar on September 19, 2024 - Register Today!

Tue, 2024-07-30 13:24
Notice NOT-OD-24-160 from the NIH Guide for Grants and Contracts

Notice of Informational Webinar for the NIGMS Innovative Programs to Enhance Research Training (IPERT) Program (R25)

Tue, 2024-07-30 13:17
Notice NOT-GM-24-047 from the NIH Guide for Grants and Contracts

Request for Information (RFI) on the National Institute on Aging (NIA) Strategic Directions for Research

Tue, 2024-07-30 13:16
Notice NOT-AG-24-028 from the NIH Guide for Grants and Contracts

Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)

Tue, 2024-07-30 13:14
Funding Opportunity RFA-AI-24-041 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support exploratory and conceptual research projects in radiation research focused on medical countermeasures, biodosimetry, and animal model development to diagnose/mitigate/treat injuries arising from radiation exposure during a public health emergency. This NOFO is intended to support development of preliminary data to help advance high-risk, high-reward projects needed for a robust early product development pipeline that can lead to the advancement of much-needed radiation-exposure related tools and products.

Notice to Extend the Expiration Date of PAR-22-025, "NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)"

Tue, 2024-07-30 06:07
Notice NOT-DC-24-036 from the NIH Guide for Grants and Contracts

Pages